Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Abbott Laboratories

Share:
Related ABT
Here Are All The Big Biotech Mergers In 2016
St. Jude's Abbott Merger On Track For Q4
St. Jude Medical: A Great Short With 2.5x Risk/Reward (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Abbott Laboratories (NYSE: ABT), but lowered its price target from $87.00 to $39.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Abbott Laboratories closed on Tuesday at $33.36.

Latest Ratings for ABT

DateFirmActionFromTo
Aug 2016JefferiesMaintainsBuy
Jul 2016JefferiesMaintainsBuy
Jun 2016Edward JonesUpgradesHoldBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!